Levetiracetam monotherapy for children and adolescents with benign rolandic seizures

Seizure

Volumn 16, Issue 3, 2007, Pages 271-275

  Verrotti, A ^a   Coppola, G ^b   Manco, R ^a   Ciambra, G ^c   Iannetti, P ^c   Grosso, S ^d   Balestri, P ^d   Franzoni, E ^e   Chiarelli, F ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiepileptic drugs; Benign epilepsy with centrotemporal spikes; Levetiracetam

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; OXCARBAZEPINE; VALPROIC ACID;

ADOLESCENT; ARTICLE; BENIGN CHILDHOOD EPILEPSY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DROWSINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IRRITABILITY; MALE; MONOTHERAPY; MULTICENTER STUDY; NEUROTOXICITY; PHYSICAL DISEASE; PRIORITY JOURNAL; ROLANDIC EPILEPSY; SIDE EFFECT; SOMNOLENCE; SPIKE WAVE; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ANTICONVULSANTS; CHILD; ELECTROENCEPHALOGRAPHY; EPILEPSY, ROLANDIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PIRACETAM; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33847417063     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2006.12.006     Document Type: Article

References (33)

1. Panayiotopoulos C.P. Benign childhood partial seizures and related epileptic syndromes (1999), John Libbey and Company Ltd., London
2. Verrotti A., Latini G., Trotta D., Giannuzzi R., Cutarella R., Morgese G., et al. Typical an atypical rolandic epilepsy in childhood: a follow-up study. Pediatric Neurol 26 (2002) 26-29
3. Commission, on Classification and Terminology of the International League Against Epilepsy: Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30:389-99.
4. Panayiotopoulos C.P. Benign childhood epilepsy with centrotemporal spikes. In: Panayiotopoulos C.P. (Ed). The epilepsies. Seizures, syndromes and management (2005), Bladon Medical Publishing, Chipping Norton 224-234
5. Hamada Y., Okuno T., Hattori H., and Mikawa H. Indication for anti-epileptic drug treatment of benign childhood epilepsy with centro-temporal spikes. Brain Dev 16 (1994) 159-161
6. Galanopoulou A.S., Bojko A., Lado F., and Moshè S.L. The spectrum of neuropsychiatric abnormalities associated with electrical status epilepticus in sleep. Brain Dev 22 (2000) 279-295
7. Pellock J.M., Glauser T.A., Bebin E.M., Fountain N.B., Ritter F.J., Coupez R.M., et al. Pharmacokinetic study of Levetiracetam in children. Epilepsia 42 (2001) 1574-1579
8. Klitgaard H., and Pitkanen A. Antiepileptogenesis, neuroprotection and disease modification in the treatment of epilepsy: focus on Levetiracetam. Epileptic Disord 5 Suppl. 1 (2003) S9-S16
9. Noyer M., Gillard M., and Matagne A. The novel antiepileptic drug Levetiracetam (UCB L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 286 (1995) 137-146
10. Birnstiel S., Wulfert E., and Beck S.G. Levetiracetam (UCB L059) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission. Naunyn Schmiedebergs Arch Pharmacol 356 (1997) 611-618
11. Rigo J.M., Hans G., and Nguyer L. The antiepileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA-and glycine-gated currents. Br J Pharmacol 136 (2002) 659-672
12. Zona C., Niespodziany I., Marchetti C., Klitgaard H., Bernardi G., and Margineanu D.G. Levetiracetam does not modulate neuronal voltage-gated Na + and T-type Ca2 + currents. Seizures 10 (2001) 279-286
13. Cereghino J.J., Biton V., Abou-khalil B., Dreifuss F., Ganer L.J., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
14. Ben-Menachem E., and Falter U. Efficacy and tolerability of Levetiracetam 3000 mg in patients with refractorial partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41 (2000) 1276-1283
15. Shorvon S.D., and van Rijckevorsel K. A new antiepileptic drug. J Neurol Neurosurg Psychiatr 72 (2002) 426-428
16. French J., Edrich P., and Cramer J.A. A systematic review of the safety profile of Levetiracetam: a new antiepileptic drug. Epilepsy 47 (2001) 77-90
17. Marson A.G., Hutton J.L., Leach J.P., Castillo S., Schmidt D., White S., et al. Levetiracetam, oxocarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 46 (2001) 259-270
18. Tsai J.J., Yen D.J., Hsih M.S., Chen S.S., Hiersemenzel R., Edrich P., et al. Efficacy and Safety or Levetiracetam (up to 2000 mg/day) in Taiwanese Patients with Refractory Partial Seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia 47 (2006) 72-81
19. Shorvon S.D., Lowenthal A., Janz D., Bielen E., and Loislan P. Multicenter double-blind, randomized, placebo-controlled trial of Levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41 (2000) 1179-1186
20. Grosso S., Franzoni E., Coppola G., Iannetti P., Verrotti A., Cordelli D.M., et al. Efficacy and safety of Levetiracetam: an add-on trial in children with refractory epilepsy. Seizures 14 (2005) 248-253
21. Mohanraj R., Parker P.G., Stephen L.J., and Brodie M.J. Levetiracetam in refractory epilepsy: a prospective observational study. Seizures 14 (2005) 23-27
22. Bello-Espinoza L.E., and Roberts S.L. Levetiracetam for benign epilepsy of childhood with centrotemporal spikes-three cases. Seizure 12 (2003) 157-159
23. Lundberg S., and Eeg O. Rolandic epilepsy: a challenge in terminology and classification. Eur J Paediatr Neurol 7 (2003) 239-241
24. Lage L., Buyse G., Deconinck A., and Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Paediatr Neurol 7 (2003) 123-128
25. Kossoff E.H., Boatman D., and Freeman J.M. Landau-Kleffner syndrome responsive to levetiracetam. Epilepsy Behav 4 (2003) 571-575
26. Al Twajri W.A., and Shevell M.I. Atypical benign epilepsy of childhood with rolandic spikes: features of a subset requiring more than one medication for seizure control. J Child Neurol 17 (2002) 901-904
27. Glauser T.A., Pellock J.M., Bebin E.M., Fountain N.B., Ritter F.J., Jensen C.M., et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 43 (2002) 518-524
28. Glauser T.A., and Dulac O. Preliminary efficacy of levetiracetam in children. Epileptic Disord 5 Suppl. 1 (2003) S45-S50
29. Herranz J.L. Levetiracetam in children and adolescents with epilepsy. Revue Neurologie 37 (2003) 558-560
30. Kossoff E.H., Bergey G.K., Freeman J.M., and Vining E.P. Levetiracetam psychosis in children with epilepsy. Epilepsia 42 (2001) 1611-1613
31. Mula M., Trimble M.R., and Sander J.W. Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam. Seizures 13 (2004) 55-57
32. Mula M., Trimble M.R., Yuen A., Liu R.S., and Sander J.W. Psychiatric adverse events during levetiracetam therapy. Neurology 63 (2003) 704-706
33. Morrell M.J., Leppik I., French J., Ferrendelli J., Han J., and Maqnus L. The Keeper trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res 54 (2003) 153-161